[go: up one dir, main page]

PE20061245A1 - Composiciones para la transmision transmucosa oral de la metformina - Google Patents

Composiciones para la transmision transmucosa oral de la metformina

Info

Publication number
PE20061245A1
PE20061245A1 PE2006000346A PE2006000346A PE20061245A1 PE 20061245 A1 PE20061245 A1 PE 20061245A1 PE 2006000346 A PE2006000346 A PE 2006000346A PE 2006000346 A PE2006000346 A PE 2006000346A PE 20061245 A1 PE20061245 A1 PE 20061245A1
Authority
PE
Peru
Prior art keywords
metformin
acidonic
oral
pharmaceutical agent
transmucous
Prior art date
Application number
PE2006000346A
Other languages
English (en)
Inventor
Anna E Gluskin
Qazi Muhammad Waseem T
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of PE20061245A1 publication Critical patent/PE20061245A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION DE METFORMINA DE TRANSMUCOSA ORAL QUE CONSISTE EN: UN AGENTE FARMACEUTICO QUE CONSISTE EN METFORMINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE Y UNA CANTIDAD DE POR LO MENOS UN ACELERADOR DE LA ABSORCION SELECCIONADO DE GLICERINA, LECITINA, ACIDO HIALURONICO, ACIDO GLICOLICO, ENTRE OTROS EN EL CUAL EL AGENTE FARMACEUTICO ESTA PRESENTE EN UNA CONCENTRACION DE 5 A 90% p/p BASADO EN EL PESO TOTAL DE LA PREPARACION. SE REFIERE TAMBIEN A UN PROCESO PARA LA ELABORACION. LA CANTIDAD DEL AGENTE FARMACEUTICO QUE CONSISTE EN METFORMINA ES DE 100 A 850mg POR DOSIS Y ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES COMO DIABETES
PE2006000346A 2005-03-30 2006-03-29 Composiciones para la transmision transmucosa oral de la metformina PE20061245A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66647505P 2005-03-30 2005-03-30

Publications (1)

Publication Number Publication Date
PE20061245A1 true PE20061245A1 (es) 2007-01-06

Family

ID=37052910

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000346A PE20061245A1 (es) 2005-03-30 2006-03-29 Composiciones para la transmision transmucosa oral de la metformina

Country Status (16)

Country Link
US (1) US20090069437A1 (es)
EP (1) EP1863465A4 (es)
JP (1) JP2008534523A (es)
AR (1) AR052960A1 (es)
AU (1) AU2006228949A1 (es)
BR (1) BRPI0611555A2 (es)
CA (1) CA2603450A1 (es)
CR (1) CR9363A (es)
IL (1) IL185931A0 (es)
MX (1) MX2007012047A (es)
NZ (1) NZ560990A (es)
PE (1) PE20061245A1 (es)
RU (2) RU2409357C2 (es)
UY (1) UY29445A1 (es)
WO (1) WO2006102752A1 (es)
ZA (1) ZA200708834B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080025A1 (en) * 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum comprising metformin
KR20100102631A (ko) * 2008-01-16 2010-09-24 얀센 파마슈티카 엔.브이. 메트포르민 및 ｍｐｔ 저해제의 배합물
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
WO2010062861A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
US20120128770A1 (en) * 2009-06-24 2012-05-24 Kobenhavns Universitet Treatment of insulin resistance and obesity by stimulating glp-1 release
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EP3696281A1 (en) * 2019-02-13 2020-08-19 Johann Wolfgang Goethe-Universität Frankfurt am Main Arginase as biomarker and drug target for pcos
US12303479B2 (en) * 2019-05-06 2025-05-20 The Regents Of The University Of California Chloride intracellular channel 1 for regulation of food intake

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161428C (da) * 1985-05-10 1991-12-16 Fertin Lab As Fast, oralt cariesmodvirkende middel
DK365389D0 (da) * 1989-07-24 1989-07-24 Fertin Lab As Antifungalt tyggegummipraeparat
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
AU3536299A (en) * 1998-04-29 1999-11-16 Sumitomo Pharmaceuticals Company, Limited Oral formulation comprising biguanide and an organic acid
DE69818444T2 (de) * 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6344222B1 (en) * 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
KR20030061392A (ko) * 2000-11-03 2003-07-18 안드렉스 코포레이션 방출 조절성 메트포민 조성물
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
WO2004026241A2 (en) * 2002-09-20 2004-04-01 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
JP2007509975A (ja) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン ギャバペンチン及びプレギャバリンの増加された吸収のための組成物及び投与形態物

Also Published As

Publication number Publication date
BRPI0611555A2 (pt) 2010-09-21
JP2008534523A (ja) 2008-08-28
CR9363A (es) 2008-02-12
US20090069437A1 (en) 2009-03-12
ZA200708834B (en) 2008-11-26
EP1863465A4 (en) 2010-12-15
RU2007139886A (ru) 2009-05-10
EP1863465A1 (en) 2007-12-12
NZ560990A (en) 2009-02-28
AR052960A1 (es) 2007-04-11
CA2603450A1 (en) 2006-10-05
WO2006102752A1 (en) 2006-10-05
MX2007012047A (es) 2007-12-12
AU2006228949A1 (en) 2006-10-05
RU2409357C2 (ru) 2011-01-20
IL185931A0 (en) 2008-02-09
UY29445A1 (es) 2006-10-02
RU2010139163A (ru) 2012-03-27

Similar Documents

Publication Publication Date Title
PE20080658A1 (es) Formulaciones de metilnaltrexona en forma de polvo seco
BRPI0508540A8 (pt) Composto, composição farmacêutica, e, uso de um composto
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
GT200900154A (es) Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
PE20080698A1 (es) Composiciones farmaceuticas de inhibidores de dpp iv
CO6270215A2 (es) Trans-clomifeno para el sindrome metabolico
CY1115825T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους
PE20091184A1 (es) Formas de dosificacion farmaceutica
EA201100896A1 (ru) Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение
AR050418A1 (es) Dosificacion fija de anticuerpos her
CL2008003582A1 (es) Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
PE20061245A1 (es) Composiciones para la transmision transmucosa oral de la metformina
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
ECSP088240A (es) Composición de trazodona para administración una vez por día
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
RU2013110003A (ru) Комбинация соединений для лечения или предотвращения кожных заболеваний
BRPI0414500A (pt) formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
MX2009004692A (es) Composicion para el tratamiento de afecciones de la piel.
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
BRPI0515261A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo

Legal Events

Date Code Title Description
FC Refusal